Q3 EPS Forecast for Cogent Biosciences Raised by Analyst

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Cogent Biosciences to ($0.59), with a current buy rating and target price of $21.00.
• Several investment firms have recently increased their price targets for Cogent Biosciences, with Jefferies Financial Group setting the target at $28.00 and Citigroup at $22.00.
• Director Fairmount Funds Management significantly increased their stake in the company by acquiring nearly 2.78 million shares for about $25 million, raising their ownership to approximately 9 million shares.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Cogent Biosciences in a research report issued to clients and investors on Wednesday, August 6th. HC Wainwright analyst R. Burns now expects that the technology company will post earnings per share of ($0.59) for the quarter, up from their prior forecast of ($0.60). HC Wainwright has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.53) EPS, Q1 2026 earnings at ($0.59) EPS, Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($2.15) EPS.

Other equities analysts have also recently issued research reports about the company. Leerink Partners raised their target price on Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. Citigroup raised their target price on Cogent Biosciences from $15.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, July 18th. Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. Robert W. Baird raised their target price on Cogent Biosciences from $7.00 to $9.00 and gave the stock a "neutral" rating in a report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. raised their target price on Cogent Biosciences from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Cogent Biosciences currently has an average rating of "Moderate Buy" and an average target price of $18.70.

Cogent Biosciences Stock Performance

COGT traded up $0.60 during midday trading on Friday, reaching $11.53. 541,427 shares of the company were exchanged, compared to its average volume of 2,000,448. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.97. The stock has a market capitalization of $1.31 billion, a P/E ratio of -6.48 and a beta of 0.36. The stock's 50-day simple moving average is $9.35 and its 200 day simple moving average is $7.37.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The technology company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02.

Insider Buying and Selling at Cogent Biosciences

In other Cogent Biosciences news, Director Fairmount Funds Management Llc acquired 2,777,777 shares of the business's stock in a transaction dated Thursday, July 10th. The shares were acquired at an average price of $9.00 per share, for a total transaction of $24,999,993.00. Following the acquisition, the director directly owned 9,003,418 shares of the company's stock, valued at approximately $81,030,762. This trade represents a 44.62% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.29% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cogent Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Cogent Biosciences in the 1st quarter valued at approximately $36,000. CWM LLC raised its position in Cogent Biosciences by 11,869.9% in the 1st quarter. CWM LLC now owns 8,738 shares of the technology company's stock valued at $52,000 after buying an additional 8,665 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Cogent Biosciences in the 4th quarter valued at approximately $78,000. Hsbc Holdings PLC acquired a new stake in Cogent Biosciences in the 4th quarter valued at approximately $81,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Cogent Biosciences in the 4th quarter valued at approximately $88,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.